Data completeness
2/8 — Basic
SORBITRATE (isosorbide dinitrate) by AstraZeneca is clinical pharmacology the principal pharmacological action of isosorbide dinitrate is relaxation of vascular smooth muscle and consequent dilatation of peripheral arteries and veins, especially the latter. Approved for heart failure, diabetes.
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SORBITRATE (isosorbide dinitrate) is an organic nitrate vasodilator administered sublingually as a tablet for acute angina relief and chronic heart failure management. It works by relaxing vascular smooth muscle, dilating peripheral arteries and veins, reducing cardiac preload and afterload, and increasing coronary blood flow. The drug is particularly effective for patients with angina pectoris and those with heart failure who require rapid symptom relief.
Pre-Launch
Pre-launch status suggests active commercial infrastructure building with expanding Medical Affairs and Commercial teams preparing for market entry.
Mechanism of Action
CLINICAL PHARMACOLOGY The principal pharmacological action of isosorbide dinitrate is relaxation of vascular smooth muscle and consequent dilatation of peripheral arteries and veins, especially the latter. Dilatation of the veins promotes peripheral pooling of blood and decreases venous return to…
Worked on SORBITRATE at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.